Literature DB >> 2832961

Activated alveolar macrophages in subclinical pulmonary inflammation in collagen vascular diseases.

B Wallaert1, F Bart, C Aerts, A Ouaissi, P Y Hatron, A B Tonnel, C Voisin.   

Abstract

A study was initiated to determine whether alveolar macrophages from patients with collagen vascular diseases but free of pulmonary symptoms were spontaneously activated and whether they released various mediators related to the pathogenesis of pulmonary fibrosis. Alveolar macrophages obtained by bronchoalveolar lavage from 32 patients with proved collagen vascular disease but no evidence of lung disease were compared with those from 10 patients with collagen vascular disease with interstitial lung disease (CVD-ILD) and from 10 healthy controls. The total number of alveolar macrophages did not differ between patients with collagen vascular disease and controls but were substantially increased in the CVD-ILD group. Alveolar macrophages from 31 of the 32 patients with collagen vascular disease and from all 10 in the CVD-ILD group had at least one criterion of activation. Neutrophil chemotactic activity was detected in supernatants from alveolar macrophage culture in 23 of the 32 patients with collagen vascular disease and from nine of the 10 in the CVD-ILD group; fibronectin secretion by alveolar macrophages was increased in 12 of the 32 patients with collagen vascular disease and in nine of the 10 in the CVD-ILD group. Furthermore, alveolar macrophages from 20 of the 32 patients with collagen vascular disease and four of the 10 CVD-ILD patients spontaneously released increased amounts of superoxide anion. Thus alveolar macrophages were spontaneously activated in a high proportion of patients with collagen vascular disease.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2832961      PMCID: PMC461084          DOI: 10.1136/thx.43.1.24

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  32 in total

Review 1.  Interstitial pulmonary fibrosis--which cell is the culprit?

Authors:  G L Snider
Journal:  Am Rev Respir Dis       Date:  1983-05

Review 2.  Interstitial lung diseases of unknown cause. Disorders characterized by chronic inflammation of the lower respiratory tract (first of two parts).

Authors:  R G Crystal; P B Bitterman; S I Rennard; A J Hance; B A Keogh
Journal:  N Engl J Med       Date:  1984-01-19       Impact factor: 91.245

3.  The regulation of lung fibroblast proliferation by alveolar macrophages in experimental silicosis.

Authors:  E M Lugano; J H Dauber; J A Elias; R I Bashey; S A Jimenez; R P Daniele
Journal:  Am Rev Respir Dis       Date:  1984-05

4.  Mixed connective tissue disease--an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA).

Authors:  G C Sharp; W S Irvin; E M Tan; R G Gould; H R Holman
Journal:  Am J Med       Date:  1972-02       Impact factor: 4.965

Review 5.  Idiopathic pulmonary fibrosis. Clinical, histologic, radiographic, physiologic, scintigraphic, cytologic, and biochemical aspects.

Authors:  R G Crystal; J D Fulmer; W C Roberts; M L Moss; B R Line; H Y Reynolds
Journal:  Ann Intern Med       Date:  1976-12       Impact factor: 25.391

6.  Immune reactions in the lungs of asymptomatic dairy farmers.

Authors:  P Solal-Céligny; M Laviolette; J Hébert; Y Cormier
Journal:  Am Rev Respir Dis       Date:  1982-12

7.  Mechanisms of pulmonary fibrosis. Spontaneous release of the alveolar macrophage-derived growth factor in the interstitial lung disorders.

Authors:  P B Bitterman; S Adelberg; R G Crystal
Journal:  J Clin Invest       Date:  1983-11       Impact factor: 14.808

8.  Acute non-specific inflammation and modification of macrophage and lymphocyte functions.

Authors:  J P Giroud; Y C Sheng; M Pelletier; I Florentin; J Bird
Journal:  Br J Dermatol       Date:  1983-07       Impact factor: 9.302

9.  Involvement of immunoglobulin E in the secretory processes of alveolar macrophages from asthmatic patients.

Authors:  M Joseph; A B Tonnel; G Torpier; A Capron; B Arnoux; J Benveniste
Journal:  J Clin Invest       Date:  1983-02       Impact factor: 14.808

10.  Lymphokines enhance the capacity of human monocytes to secret reactive oxygen intermediates.

Authors:  A Nakagawara; N M DeSantis; N Nogueira; C F Nathan
Journal:  J Clin Invest       Date:  1982-11       Impact factor: 14.808

View more
  6 in total

1.  The distribution of phenotypically distinct macrophage subsets in the lungs of patients with cryptogenic fibrosing alveolitis.

Authors:  B Noble; R M Du Bois; L W Poulter
Journal:  Clin Exp Immunol       Date:  1989-04       Impact factor: 4.330

Review 2.  Subclinical alveolitis in immunologic systemic disorders.

Authors:  B Wallaert
Journal:  Lung       Date:  1990       Impact factor: 2.584

3.  Imaging of pulmonary disease in rheumatoid arthritis using J001X scintigraphy: preliminary results.

Authors:  P Goupille; P Diot; J P Valat; E Lemarie; C Valat; E Asquier; A Delarue; A Le Pape
Journal:  Eur J Nucl Med       Date:  1995-12

4.  Imaging of pulmonary disease in scleroderma with J001X scintigraphy.

Authors:  P Diot; E Diot; E Lemarie; J L Guilmot; J L Baulieu; E Asquier; C Valat; A Delarue; A Le Pape
Journal:  Thorax       Date:  1994-05       Impact factor: 9.139

5.  Depletion of Alveolar Macrophages Does Not Prevent Hantavirus Disease Pathogenesis in Golden Syrian Hamsters.

Authors:  Christopher D Hammerbeck; Rebecca L Brocato; Todd M Bell; Christopher W Schellhase; Steven R Mraz; Laurie A Queen; Jay W Hooper
Journal:  J Virol       Date:  2016-06-24       Impact factor: 5.103

Review 6.  Bronchoalveolar lavage.

Authors:  W R Martin; P A Padrid; C E Cross
Journal:  Clin Rev Allergy       Date:  1990 Summer-Fall
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.